Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Jochen J. Frietsch - , Friedrich Schiller University Jena, University of Würzburg (Author)
  • Sarah Flossdorf - , Deutsches Register für Stammzelltransplantationen e. V., University of Duisburg-Essen (Author)
  • James F. Beck - , Friedrich Schiller University Jena (Author)
  • Nicolaus Kröger - , Deutsches Register für Stammzelltransplantationen e. V., University of Hamburg (Author)
  • Katharina Fleischhauer - , Deutsches Register für Stammzelltransplantationen e. V., University of Duisburg-Essen (Author)
  • Peter Dreger - , Deutsches Register für Stammzelltransplantationen e. V., Heidelberg University  (Author)
  • Johannes Schetelig - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Deutsches Register für Stammzelltransplantationen e. V. (Author)
  • Martin Bornhäuser - , Department of Internal Medicine I, University Cancer Centre Dresden (Author)
  • Andreas Hochhaus - , Friedrich Schiller University Jena (Author)
  • Inken Hilgendorf - , Friedrich Schiller University Jena (Author)

Abstract

Young adults (YA) represent a minority among recipients of allogeneic haematopoietic stem cell transplantation (HSCT). In order to describe the outcome of YA following HSCT in Germany, 9299 patients who were registered with the German Registry for Stem Cell Transplantation were included in this retrospective analysis of the years 1998–2019. The impact of the variables, such as patient age and sex, sex differences, stem cell source, donor type, conditioning, year of HSCT, the diagnosis, and the achieved remission status were tested in univariable and multivariable analysis for overall, event-free and relapse-free survival as well as for the cumulative incidences of non-relapse and therapy-related mortality. Altogether, the outcome of YA after HSCT improved over time and was determined by the underlying disease, the age at disease onset, stem cell source, and donor type. Patients were most likely to die from relapse, and survival of HSCT recipients after 10 years was reduced by more than half in comparison to the general population of YA. Deeper understanding of modifiable risk factors may be gained by studies comparing the outcome of YA post-HSCT with that of children, adolescents and elderly patients. A deliberate and strong patient selection may further improve mortality rates.

Details

Original languageEnglish
Pages (from-to)308-318
Number of pages11
JournalBritish journal of haematology
Volume201 (2023)
Issue number2
Publication statusPublished - 27 Dec 2022
Peer-reviewedYes

External IDs

PubMed 36573337

Keywords

ASJC Scopus subject areas

Keywords

  • AYA, adolescents and young adults, allogeneic haematopoietic stem cell transplantation, outcome, survival, Recurrence, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Risk Factors, Male, Young Adult, Adolescent, Female, Aged, Retrospective Studies, Tissue Donors, Transplantation Conditioning, Child

Library keywords